
Phase 2b REZOLVE-AD trial data show rezpegaldesleukin improves skin symptoms and asthma control in adults with moderate-to-severe atopic dermatitis.

Jonathan Corren, MD, associate clinical professor of medicine and pediatrics at the David Geffen School of Medicine, University of California, Los Angeles.

Phase 2b REZOLVE-AD trial data show rezpegaldesleukin improves skin symptoms and asthma control in adults with moderate-to-severe atopic dermatitis.